Completed PHASE4 NCT00363311

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Prostate

Interventions Dutasteride Matching placebo

Updated 7 times since 2017 Last updated: Nov 30, 2016 Started: Jul 31, 2006 Primary completion: Mar 31, 2010 Completion: Jul 31, 2010

Listed as NCT00363311, this PHASE4 trial focuses on Neoplasms, Prostate and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Annapolis, United States , Bala-Cynwyd, United States , Barrie, Canada , Beverly Hills, United States , Brampton, Canada , Brantford, Canada , Burlington, Canada , Chicago, United States and 67 more locations